ES2118726T3 - Factor de crecimiento epidermal como medicamento para la restauracion de neuronas de la substantia nigra en el tratamiento de trastornos neurodegenerativos. - Google Patents

Factor de crecimiento epidermal como medicamento para la restauracion de neuronas de la substantia nigra en el tratamiento de trastornos neurodegenerativos.

Info

Publication number
ES2118726T3
ES2118726T3 ES91106438T ES91106438T ES2118726T3 ES 2118726 T3 ES2118726 T3 ES 2118726T3 ES 91106438 T ES91106438 T ES 91106438T ES 91106438 T ES91106438 T ES 91106438T ES 2118726 T3 ES2118726 T3 ES 2118726T3
Authority
ES
Spain
Prior art keywords
treatment
growth factor
neurons
medication
restoration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91106438T
Other languages
English (en)
Inventor
Angelo Carenzi
Gianni Pezzoli
Sante Ricciardi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zambon Group SpA
Zambon SpA
Original Assignee
Zambon Group SpA
Zambon SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Group SpA, Zambon SpA filed Critical Zambon Group SpA
Application granted granted Critical
Publication of ES2118726T3 publication Critical patent/ES2118726T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES FARMACEUTICAS QUE CONTIENEN FACTOR DE CRECIMIENTO EPIDERMICO (EGF) COMO INGREDIENTE ACTIVO Y SU USO EN EL TRATAMIENTO DE TRASTORNOS NEURODEGENERATIVOS.
ES91106438T 1990-04-26 1991-04-22 Factor de crecimiento epidermal como medicamento para la restauracion de neuronas de la substantia nigra en el tratamiento de trastornos neurodegenerativos. Expired - Lifetime ES2118726T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT20144A IT1240683B (it) 1990-04-26 1990-04-26 Composizione farmaceutica contenente egf

Publications (1)

Publication Number Publication Date
ES2118726T3 true ES2118726T3 (es) 1998-10-01

Family

ID=11164158

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91106438T Expired - Lifetime ES2118726T3 (es) 1990-04-26 1991-04-22 Factor de crecimiento epidermal como medicamento para la restauracion de neuronas de la substantia nigra en el tratamiento de trastornos neurodegenerativos.

Country Status (6)

Country Link
US (1) US5200396A (es)
EP (1) EP0454026B1 (es)
AT (1) ATE167060T1 (es)
DE (1) DE69129563T2 (es)
ES (1) ES2118726T3 (es)
IT (1) IT1240683B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4237047A1 (en) * 1991-11-04 1993-05-06 I N R O Handels-Gmbh, 8750 Aschaffenburg, De Drug contg. polypeptide homologous to nerve growth factor and slow virus sequence - for treating amyotrophic lateral sclerosis, spinal muscle atrophy or Parkinson's disease
FR2684301B1 (fr) * 1991-12-02 1995-03-24 Synthelabo Composition pharmaceutique contenant de l'egf pour le traitement des pathologies bronchopulmonaires.
WO1994009371A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Antemortem diagnostic test for alzheimer's disease
CN1141058A (zh) * 1993-11-09 1997-01-22 纽罗斯菲里斯控股有限公司 中枢神经系统干细胞的原位修饰和处理
EP0743066A3 (en) * 1995-05-16 1998-09-30 Mitsui Pharmaceuticals, Inc. Wound-healing agent
WO2002102319A2 (en) * 2001-06-14 2002-12-27 Bristol-Myers Squibb Company Polynucleotide encoding a novel human growth factor with homology to epidermal growth factor, bgs-8, expressed highly in immune tissue
AU2003245089A1 (en) * 2002-07-03 2004-01-23 Nexgen Biotechnologies, Inc. Fusion polypeptide comprising epidermal growth factor and human serum albumin
ES2304818B1 (es) * 2005-05-23 2009-10-26 Universidad Del Pais Vasco Metodos para el diagnostico y pronostico de las enfermedades desmielinizantes y para el desarrollo de medicamentos contra las enfermedades desmielinizantes.
CN101897953B (zh) * 2009-05-27 2013-03-27 中国人民解放军军事医学科学院毒物药物研究所 无创性高穿透性表皮生长因子及其应用
WO2013166487A1 (en) 2012-05-04 2013-11-07 Yale University Highly penetrative nanocarriers for treatment of cns disease
CN103204920A (zh) * 2013-04-28 2013-07-17 中国人民解放军军事医学科学院毒物药物研究所 一种新型表皮生长因子及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE38892B1 (en) * 1973-03-28 1978-06-21 Ici Ltd Pharmaceutical compositions
JPH0611709B2 (ja) * 1984-10-19 1994-02-16 チロン コーポレイション 角膜基質創傷の治療のための組成物
NZ222413A (en) * 1986-11-05 1991-06-25 Ethicon Inc Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser
US4861757A (en) * 1986-11-14 1989-08-29 Institute Of Molecular Biology Wound healing and bone regeneration using PDGF and IGF-I
US5057494A (en) * 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
US5036046A (en) * 1988-10-12 1991-07-30 Eye Research Institute Of Retina Foundation, Inc. Method for enhancing healing of corneal endothelial wounds
WO1990011781A1 (en) * 1989-04-04 1990-10-18 Alcon Laboratories, Inc. The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions
JP3187410B2 (ja) * 1989-08-10 2001-07-11 住友製薬株式会社 脳内投与用徐放性製剤

Also Published As

Publication number Publication date
IT1240683B (it) 1993-12-17
DE69129563T2 (de) 1999-01-07
ATE167060T1 (de) 1998-06-15
DE69129563D1 (de) 1998-07-16
US5200396A (en) 1993-04-06
EP0454026A1 (en) 1991-10-30
IT9020144A0 (it) 1990-04-26
IT9020144A1 (it) 1991-10-26
EP0454026B1 (en) 1998-06-10

Similar Documents

Publication Publication Date Title
ATE157251T1 (de) Verwendung von inositoltriphosphat zur behandlung von entzündungen
PT97689A (pt) Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida
ATE33503T1 (de) Pharmazeutische und tiermedizinische praeparate von interleukin-2, in dem cystein-125 ausgetauscht worden ist (muteine), sowie deren herstellung.
MX9304710A (es) Composicion farmaceutica y/o cosmetica y su uso.
ATE248597T1 (de) Acyclovirhaltige antiherpesarzneistift zur topischen anwendung
ES2002089T3 (es) Nuevas formulaciones farmaceuticas con liberacion programada que contienen antiflogisticos.
PT693924E (pt) Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
DE3783356D1 (de) Benzimidazolderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
ES2141706T3 (es) Formulaciones y su empleo en el tratamiento de enfermedades neurologicas.
ES2057604T3 (es) Enantiomero r de n-propargil-1-aminoindano, su preparacion y composiciones farmaceuticas que lo contienen.
DE59007178D1 (de) Verwendung alkylierter Polyethylenimine als gallensäureadsorbierende Arzneimittel sowie pharmazeutische Präparate.
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
ES2181682T3 (es) Utilizacion de licopeno para reducir la actividad de las celulas, en particular celulas cancerosas y preparaciones farmaceuticas.
ES2118726T3 (es) Factor de crecimiento epidermal como medicamento para la restauracion de neuronas de la substantia nigra en el tratamiento de trastornos neurodegenerativos.
ES2034926T1 (es) Composiciones farmaceuticas orales liquidas con actividad anti-inflamatoria.
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
ES2089687T3 (es) 4-fenil-piridonas y 4-fenil-2-alcoxipiridinas sustituidas como inhibidores de la hmg-coa-reductasa.
ATE173627T1 (de) Medizinische zusammensetzung
DE60031016D1 (de) Verwendung von Antiseptika zur Herstellung von Arzneimitteln zur Prophylaxe und Behandlung von Entzündungen im Korperinneren des Menschen
ES2077559T3 (es) Estabilizacion de proteinas terapeuticamente activas en preparados farmaceuticos.
GR1001511B (el) Στεροειδείς συν?έσεις.
ES2124861T3 (es) Derivados de aminoacidos y su utilizacion como inhibidores de la encefalinasa.
DE69927260D1 (de) Topische pharmazeutische zusammensetzung zur behandlung von haut- oder zirkulatorischen krankheiten auf inflammatorischer, immun-, proliferativer oder degenerativer basis
ES2053679T3 (es) Embonato de azelastina, procedimiento para su preparacion y preparados farmaceuticos que contienen embonato de azelastina como principio activo.
ES2057528T3 (es) Pdgf-a, pdgf-aa, pdgf-ab, procedimientos de preparacion y medicamentos que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 454026

Country of ref document: ES